Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology

05-03-2025 | Multiple Myeloma | REVIEW

Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma

Authors: Fatemeh Karimi, Mojtaba Aghaei, Najmaldin Saki

Published in: Current Treatment Options in Oncology

Login to get access

Opinion statement

Multiple myeloma (MM) is classified as a lymphoproliferative disorder that remains an incurable malignancy despite improved patient survival with new drug therapies. Polymorphisms are essential in determining the effectiveness and outcome of treatments in MM. Despite significant advances, there needs to be more understanding of the underlying biological mechanisms that determine treatment outcomes. studies show that investigating gene polymorphisms involved in drug metabolism, DNA repair, inflammation, and apoptosis pathways can predict the effectiveness of treatment in MM patients. Therefore, these findings emphasize the potential of genetic profiling for predicting treatment outcomes and tailoring treatments to individual genetic profiles, which increases the efficiency and reduces the toxicity of MM treatments.

Graphical Abstract

Literature
1.
Albagoush SA, Shumway C, Azevedo AM. Multiple Myeloma.StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.; 2024.
2.
Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, et al. Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. Hematol Rep. 2017;9(1):6887.PubMedPubMedCentralCrossRef
3.
Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221–7.PubMedPubMedCentralCrossRef
4.
5.
Rögnvaldsson S, Thorsteinsdóttir S, Kristinsson SY. Screening in Multiple Myeloma and Its Precursors: Are We There Yet? Clin Chem. 2024;70(1):128–39.PubMedCrossRef
6.
7.
Banu C, Moise A, Arion C, Coriu D, T̆nase A, Constantinescu I. Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients. J Med Life. 2011;4(3):264.
8.
Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, et al. Insulin-like growth factor-1-and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomark Prev. 2009;18(1):282–8.CrossRef
9.
Aghaei M, Khademi R, Far MAJ, Bahreiny SS, Mahdizade AH, Amirrajab N. Genetic Variants of Dectin-1 and their antifungal immunity impact in Hematologic Malignancies: A Comprehensive Systematic Review. Curr Res Trans Med. 2024:103460.
10.
Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022;97(Suppl 1):S3-s25.PubMed
11.
12.
Gordan LN, Marks SM, Xue M, Nagovski N, Lambert JH, Smith RE. Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting. Future Oncol. 2022;18(3):301–9.PubMedCrossRef
13.
Kumar SK, Callander NS, Adekola K, Anderson LD, Jr., Baljevic M, Baz R, et al. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(12):1281–301.
14.
Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang A, et al. The polymorphism IL-1β T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant. 2009;43(7):539–45.PubMedCrossRef
15.
Aghapour SA, Torabizadeh M, Bahreiny SS, Saki N, Jalali Far MA, Yousefi-Avarvand A, et al. Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review. Iran J Blood Cancer. 2024;16(2):84–101.CrossRef
16.
Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma II: association with effect of treatment. Eur J Haematol. 2012;88(2):93–117.PubMedCrossRef
17.
Mahdizade AH, Bahreiny SS, Bastani M-N, Dabbagh MR, Aghaei M, Ali Malayeri F, et al. The influence of CDKAL1 (rs7754840) gene polymorphism on susceptibility to gestational diabetes mellitus in pregnant women: a systematic review and meta-analysis. Int J Diabetes Dev Countries. 2023. https://​doi.​org/​10.​1007/​s13410-023-01272-7.
18.
Saki N, Haybar H, Aghaei M. Subject: Motivation can be suppressed, but scientific ability cannot and should not be ignored. J Transl Med. 2023;21(1):520.PubMedPubMedCentralCrossRef
19.
Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer. 2012;131(5):E636–42.PubMedCrossRef
20.
Kaushik S, Kaushik S, Sharma D. Functional Genomics. In: Ranganathan S, Gribskov M, Nakai K, Schönbach C, editors. Encyclopedia of Bioinformatics and Computational Biology. Oxford: Academic Press; 2019. p. 118–33.CrossRef
21.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–98.PubMedCrossRef
22.
Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, et al. US Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013;19(17):4559–63.PubMedCrossRef
23.
24.
Zhou S-F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38(7–8):802–32.PubMedCrossRef
25.
Obata H, Yahata T, Quan J, Sekine M, Tanaka K. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res. 2006;26(3B):2227–32.PubMed
26.
Yin J-Y, Huang Q, Yang Y, Zhang J-T, Zhong M-Z, Zhou H-H, Liu Z-Q. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics. 2009;19(3):206–16.PubMedPubMedCentralCrossRef
27.
Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2010;89:1133–40.PubMedPubMedCentralCrossRef
28.
Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol. 2006;24(1):65–97.PubMedCrossRef
29.
Kouki T, Sawai Y, Gardine CA, Fisfalen M-E, Alegre M-L, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease. J Immunol. 2000;165(11):6606–11.PubMedCrossRef
30.
Mäurer M, Loserth S, Kolb-Mäurer A, Ponath A, Wiese S, Kruse N, Rieckmann P. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+ 49) alters T-cell activation. Immunogenetics. 2002;54:1–8.PubMedCrossRef
31.
Ligers A, Teleshova N, Masterman T, Huang W, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2001;2(3):145–52.PubMedCrossRef
32.
Wang X, Zhao X, Giscombe R, Lefvert A. A CTLA-4 gene polymorphism at position− 318 in the promoter region affects the expression of protein. Genes Immun. 2002;3(4):233–4.PubMedCrossRef
33.
Qin X-Y, Lu J, Li G-X, Wen L, Liu Y, Xu L-P, et al. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Ann Hematol. 2018;97(3):485–95.PubMedCrossRef
34.
Rousset F, Garcia E, Defrance T, Péronne C, Vezzio N, Hsu DH, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992;89(5):1890–3.PubMedPubMedCentralCrossRef
35.
Péguet-Navarro J, Moulon C, Caux C, Dalbiez-Gauthier C, Banchereau J, Schmitt D. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur J Immunol. 1994;24(4):884–91.PubMedCrossRef
36.
Taga K, Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol. 1992;148(4):1143–8.PubMedCrossRef
37.
38.
Kasamatsu T, Saitoh T, Ino R, Gotoh N, Mitsui T, Shimizu H, et al. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib. Hematol Oncol. 2017;35(4):711–8.PubMedCrossRef
39.
40.
Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25(51):6817–30.PubMedCrossRef
41.
Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109(7):2700–7.PubMedCrossRef
42.
Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G. Nuclear factor kB as a target for new drug development in myeloid malignancies. Haematologica. 2007;92(9):1224–9.PubMedCrossRef
43.
Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 2006;25(51):6800–16.PubMedCrossRef
44.
Luo JL, Kamata H, Karin M. The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol. 2005;25(6):541–50.PubMedCrossRef
45.
Burstein E, Duckett CS. Dying for NF-kappaB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Opin Cell Biol. 2003;15(6):732–7.PubMedCrossRef
46.
47.
Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115–30.PubMedPubMedCentralCrossRef
48.
Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131–44.PubMedPubMedCentralCrossRef
49.
Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5(4):297–309.PubMedCrossRef
50.
Parker KM, Ma MH, Manyak S, Altamirano CV, Tang YM, Frantzen M, et al. Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma. Cancer Genet Cytogenet. 2002;137(1):43–8.PubMedCrossRef
51.
Spink CF, Gray LC, Davies FE, Morgan GJ, Bidwell JL. Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma. Cancer Lett. 2007;246(1–2):92–9.PubMedCrossRef
52.
Du J, Huo J, Shi J, Yuan Z, Zhang C, Fu W, et al. Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica. 2011;96(5):729–37.PubMedPubMedCentralCrossRef
53.
Herrero AB, Gutiérrez NC. Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival. Front Oncol. 2017;7:98.PubMedPubMedCentralCrossRef
54.
Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12(12):801–17.PubMedCrossRef
55.
Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis. 2018;7(1):8.PubMedPubMedCentralCrossRef
56.
Lin YS, Hung SC, Wei YH, Tarng DC. GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients. J Am Soc Nephrol. 2009;20(2):405–15.PubMedPubMedCentralCrossRef
57.
Singh MS, Michael M. Role of xenobiotic metabolic enzymes in cancer epidemiology. Methods Mol Biol. 2009;472:243–64.PubMedCrossRef
58.
Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med. 2011;208(3):519–33.PubMedPubMedCentralCrossRef
59.
60.
Kádár K, Kovács M, Karádi I, Melegh B, Pocsai Z, Mikala G, et al. Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res. 2008;32(10):1499–504.PubMedCrossRef
61.
Wilson CS, Seatter SC, Rodriguez JL, Bellingham J, Clair L, West MA. In vivo endotoxin tolerance: impaired LPS-stimulated TNF release of monocytes from patients with sepsis, but not SIRS. J Surg Res. 1997;69(1):101–6.PubMedCrossRef
62.
Jurisić V, Colović M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med Oncol. 2002;19(3):133–9.PubMedCrossRef
63.
64.
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–8.PubMedCrossRef
65.
Zmorzyński S, Popek-Marciniec S, Szudy-Szczyrek A, Wojcierowska-Litwin M, Korszeń-Pilecka I, Chocholska S, et al. The Association of GSTT1, GSTM1, and TNF-α Polymorphisms With the Risk and Outcome in Multiple Myeloma. Front Oncol. 2019;9:1056.PubMedPubMedCentralCrossRef
66.
Zmorzynski S, Popek-Marciniec S, Biernacka B, Szudy-Szczyrek A, Chocholska S, Styk W, et al. In Vitro Low-Bortezomib Doses Induce Apoptosis and Independently Decrease the Activities of Glutathione S-Transferase and Glutathione Peroxidase in Multiple Myeloma, Taking into Account the GSTT1 and GSTM1 Gene Variants. Genes (Basel). 2024;15(3). https://​doi.​org/​10.​3390/​genes15030387.
67.
Moehler TM, Neben K, Ho AD, Goldschmidt H. Angiogenesis in hematologic malignancies. Ann Hematol. 2001;80(12):695–705.PubMedCrossRef
68.
69.
Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 2001;276(5):3222–30.
70.
Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15(12):1950–61.PubMedCrossRef
71.
Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003;17(10):2025–31.PubMedCrossRef
72.
Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003;17(10):1961–6.PubMedCrossRef
73.
Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95(8):2630–6.PubMedCrossRef
74.
Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sørensen FB, Abildgaard N. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol. 2005;128(2):210–7.PubMedCrossRef
75.
Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6(8):3111–6.PubMed
76.
Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009;8(9):2496–508.PubMedPubMedCentralCrossRef
77.
Brito AB, Lourenço GJ, Oliveira GB, De Souza CA, Vassallo J, Lima CS. Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma. Ann Hematol. 2014;93(8):1363–9.PubMed
78.
Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res. 2010;29(1):95.PubMedPubMedCentralCrossRef
79.
Sissung TM, Peer CJ, Korde N, Mailankody S, Kazandjian D, Venzon DJ, et al. Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer Chemother Pharmacol. 2017;80(1):217–21.PubMedPubMedCentralCrossRef
80.
Kistler KD, Kalman J, Sahni G, Murphy B, Werther W, Rajangam K, Chari A. Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective. Cohort Study Clin Lymphoma Myeloma Leuk. 2017;17(2):89-96.e3.PubMedCrossRef
81.
Atrash S, Tullos A, Panozzo S, Bhutani M, Van Rhee F, Barlogie B, Usmani SZ. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5(1): e272.PubMedPubMedCentralCrossRef
82.
Koutsoukis A, Ntalianis A, Repasos E, Kastritis E, Dimopoulos MA, Paraskevaidis I. Cardio-oncology: A Focus on Cardiotoxicity. Eur Cardiol. 2018;13(1):64–9.PubMedPubMedCentralCrossRef
83.
Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC Cardiovasc Imaging. 2018;11(8):1084–93.PubMedPubMedCentralCrossRef
84.
Tantawy M, Yang G, Algubelli RR, DeAvila G, Rubinstein SM, Cornell RF, et al. Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma. Front Cardiovasc Med. 2023;10:1181806.PubMedPubMedCentralCrossRef
85.
Miyazato K, Tahara H, Hayakawa Y. Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells. Cancer Sci. 2020;111(8):2770–8.PubMedPubMedCentralCrossRef
86.
Zeidner JF, Foster MC. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML). Curr Drug Targets. 2017;18(3):304–14.PubMedCrossRef
87.
Charliński G, Vesole DH, Jurczyszyn A. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma. Cancers (Basel). 2021;13(18).
88.
Gandolfi S, Vekstein C, Laubach JP, O’Brien A, Masone K, Munshi NC, et al. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018;16(8):564–74.PubMed
89.
Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699–703.PubMedCrossRef
90.
91.
Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 1993;168(2):408–14.PubMedCrossRef
92.
Raabe T, Bukrinsky M, Currie RA. Relative contribution of transcription and translation to the induction of tumor necrosis factor-alpha by lipopolysaccharide. J Biol Chem. 1998;273(2):974–80.PubMedCrossRef
93.
Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34(5):391–9.PubMedCrossRef
94.
Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94(7):3195–9.PubMedPubMedCentralCrossRef
95.
Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, et al. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 2002;100(6):2263–5.PubMedCrossRef
96.
Du J, Yuan Z, Zhang C, Fu W, Jiang H, Chen B, Hou J. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leuk Res. 2010;34(11):1453–8.PubMedCrossRef
97.
98.
Metzger CS, Koutsimpelas D, Brieger J. Transcriptional regulation of the VEGF gene in dependence of individual genomic variations. Cytokine. 2015;76(2):519–26.PubMedCrossRef
99.
Lopes-Aguiar L, Delamain MT, Brito ABC, Lourenço GJ, Costa EFD, Oliveira GB, et al. VEGF, VEGFR2 and GSTM1 polymorphisms in Outcome of Multiple Myeloma Patients in the Thalidomide Era. Blood. 2016;128(22):4457-.
100.
Vangsted AJ, Søeby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, et al. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. BMC Cancer. 2010;10:404.PubMedPubMedCentralCrossRef
101.
Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392(6):1093–108.PubMedCrossRef
102.
Li Y, Hou J, Jiang H, Wang D, Fu W, Yuan Z, et al. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Haematologica. 2007;92(9):1246–9.PubMedCrossRef
103.
104.
105.
Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, et al. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011;286(13):11009–20.PubMedCrossRef
106.
Butrym A, Rybka J, Łacina P, Gębura K, Frontkiewicz D, Bogunia-Kubik K, Mazur G. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment. Leuk Res. 2015;39(12):1462–6.PubMedCrossRef
107.
Iskierka-Jażdżewska E, Canzian F, Stępień A, Martino A, Campa D, Stein A, et al. Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. Leuk Lymphoma. 2020;61(3):699–706.PubMedCrossRef
108.
Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;121(4):624–7.PubMedCrossRef
109.
Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014;38(1):23–8.PubMedCrossRef
110.
Thakurta A, Gandhi AK, Waldman MF, Bjorklund C, Ning Y, Mendy D, et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia. 2014;28(5):1129–31.PubMedCrossRef
111.
Huang PA, Beedie SL, Chau CH, Venzon DJ, Gere S, Kazandjian D, et al. Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Sci Rep. 2019;9(1):14884.PubMedPubMedCentralCrossRef
112.
Varga G, Mikala G, Andrikovics H, et al. NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma. Br J Haematol. 2015;168:679–88.PubMedCrossRef
113.
114.
Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia. 2014;28(9):1922–6.PubMedPubMedCentralCrossRef
115.
de Larrea CF, Díaz T, Cibeira MT, Tovar N, Navarro A, Rosiñol L, et al. Salvage therapy for multiple myeloma with lenalidomide-based regimens: impact of single nucleotide polymorphisms related to miRNA pathways. Blood. 2014;124(21):2045.CrossRef
116.
Berenson JR, Ma HM, Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol. 2001;28(6):626–33.PubMedCrossRef
117.
Butrym A, Rybka J, Łacina P, et al. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment. Leuk Res. 2015;39:1462–6.PubMedCrossRef
118.
de Larrea CF, Díaz T, Cibeira MT, et al. Salvage therapy for multiple myeloma with lenalidomide-based regimens: impact of single nucleotide polymorphisms related to miRNA pathways. Blood. 2014;124:2045.CrossRef
119.
Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–29.PubMedCrossRef
120.
121.
Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99(3):511–8.PubMedPubMedCentralCrossRef
122.
Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, et al. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015;136(8):1835–44.PubMedCrossRef
123.
Navarro A, Díaz T, Tovar N, Pedrosa F, Tejero R, Cibeira MT, et al. A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget. 2015;6(3):1874–83.PubMedPubMedCentralCrossRef
124.
Sanz-Solas A, Labrador J, Alcaraz R, Cuevas B, Vinuesa R, Cuevas MV, Saiz-Rodríguez M. Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives. J Personalized Med. 2023; 13(4). https://​doi.​org/​10.​3390/​jpm13040695.
125.
Pelon M, Krzeminski P, Tracz-Gaszewska Z, Misiewicz-Krzeminska I. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells. Front Pharmacol. 2024;15:1351565.PubMedPubMedCentralCrossRef
126.
Pan D, Richter J. Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. Front Oncol. 2021;11: 819127.PubMedCrossRef
127.
128.
Study Tests Targeted Drugs for Multiple Myeloma. Cancer Discov. 2019;9(4):459-.
129.
Metadata
Title
Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma
Authors
Fatemeh Karimi
Mojtaba Aghaei
Najmaldin Saki
Publication date
05-03-2025
Publisher
Springer US
Published in
Current Treatment Options in Oncology
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-025-01295-8

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Video
Image Credits